TGBA01AD

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 04:39, 9 September 2018 (Reverted to revision 847425101 by Medgirl131 (talk): Ref. (TW)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

TGBA01AD
Clinical data
Other namesFKB01MD
Routes of
administration		By mouth
Pharmacokinetic data
Bioavailability17%[1]
Elimination half-life4 hours[1]

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2] [1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]

See also

References

  1. ^ a b c Fabre-Kramer: FKB01MD
  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595.
  3. ^ AdisInsight: TGBA01AD

External links



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=TGBA01AD&oldid=858718842"